Compare ResMed Inc. (RMD) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Global X Uranium ETF — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Global X Uranium ETF trades at $38.81 (market cap $5.48B). The key difference: ResMed Inc. is far larger — about 5.8× Global X Uranium ETF's market cap, and ResMed Inc. pays a 1.16% dividend while Global X Uranium ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Global X Uranium ETF for 62 Days on average.
| RMD | URA | |
|---|---|---|
Market Cap | $31.89B | $5.48B |
Volume | 618,314 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $277.88 | $61.81 |
52-Week Low | $182.82 | $37.52 |
Typical Hold Time | 51 Days | 62 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
URA (Global X Uranium ETF) is trading at $38.96, down 2.43% today amid bearish technical signals. The ETF faces selling pressure with 19 sell signals versus 3 buy signals across technical indicators. Recent news highlights nuclear energy's growth potential from AI power demand and government support, though uranium ETFs have experienced volatility. The fund provides diversified exposure to uranium miners, utilities, and nuclear infrastructure companies.
The nuclear sector shows long-term potential driven by AI energy demands and government investments, but URA faces near-term technical headwinds. Key risks include commodity price volatility and concentrated holdings. Analyst sentiment remains mixed with some seeing value after recent declines while others caution about sector-specific challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
